The recognition of the role in the loss of dopaminergic neurons of the activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome by α-syn aggregates in PD pathology accounts for another pharmacological target that can be exploited for PD treatment (Gordon et al., 2018; Wang et al., 2019; Haque et al., 2020). Here, NLRP3 is linked to Parkinson disease.